Arvinas (ARVN) Equity Income (2019 - 2020)

Arvinas' (ARVN) quarterly Equity Income came in at -$1.4 million in Q2 2020, down 227.27% quarter-over-quarter from $1.1 million in Q1 2020.

Arvinas (ARVN) Equity Income (2019 - 2020) Analysis & Trends

Arvinas' Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2020.

  • On a quarterly basis, Equity Income changed N/A year-over-year to -$1.4 million in Q2 2020; TTM through Jun 2020 was $49.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $49.8 million, changed N/A from the prior year.
  • Equity Income retreated to -$1.4 million in Q2 2020 per ARVN's latest filing, from $1.1 million in the prior quarter.
  • Across five years, Equity Income topped out at $99.3 million in Q4 2019 and bottomed at -$49.5 million in Q3 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Equity Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn -
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Arvinas 512.64 Mn -102.26 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2020 -1.40 Mn
Mar 31, 2020 1.10 Mn
Dec 31, 2019 99.30 Mn
Sep 30, 2019 -49.50 Mn